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PURPOSE. To assess if ripasudil has a neuroprotective effect using mice with excitatory amino
acid carrier 1 (EAAC1) deletion (EAAC1 knockout [KO] mice), a mouse model of normal
tension glaucoma.
METHODS. Topical administration (5 lL/day) of two different concentrations of ripasudil (0.4%
and 2%) were applied to EAAC1 KO mice from 5 to 12 weeks old. Optical coherence
tomography, multifocal electroretinograms, the measurement of intraocular pressure (IOP),
and histopathology analyses were performed at 5, 8, and 12 weeks old. Retrograde labeling of
retinal ganglion cells (RGCs), immunoblot, and immunohistochemical analyses of phosphor-
ylated p38 mitogen-activated protein kinase (MAPK) in the retina were performed at 8 weeks
old.
RESULTS. Topical ripasudil ameliorated retinal degeneration and improved visual function in
EAAC1 KO mice at both 8 and 12 weeks old. Ripasudil reduced IOP and strongly suppressed
the phosphorylation of p38 MAPK that stimulates RGC death in EAAC1 KO mice.
CONCLUSIONS. These results suggest that, in addition to IOP reduction, ripasudil prevents
glaucomatous retinal degeneration by neuroprotection, which is achieved by suppressing cell-
death signaling pathways.
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Normal tension glaucoma (NTG) is a subtype of glaucomathat presents with statistically normal intraocular pressure
(IOP), suggesting the possibility that non-IOP-dependent
factors may contribute to the disease progression.1,2 We
previously reported that loss of glutamate transporters (excit-
atory amino acid carrier 1 [EAAC1] or glutamate/aspartate
transporter [GLAST]) in mice leads to progressive retinal
ganglion cell (RGC) loss and optic nerve degeneration while
maintaining normal IOP, demonstrating pathological features
that are similar to NTG.3,4 EAAC1 is expressed on RGCs5 and
transports glutamate into cells together with cysteine and
glycine, which are converted to glutathione, a major antioxi-
dant in the retina.6 Thus, RGC loss in EAAC1 knockout (KO)
mice may be due to increased oxidative stress through the
formation of reactive oxygen species (ROS).2,3 Retinal degen-
eration of EAAC1 KO mice was suppressed by administration of
edaravone, a free radical scavenger, and spermidine, an
antioxidant polyamine.7,8 Oxidative stress is an important risk
factor in human glaucoma,9 and glaucoma patients show
downregulation of glutamate transporters and glutathione
levels,10,11 suggesting that these mice may be useful as animal
models of NTG.
Rho-associated protein kinase (ROCK) is a serine/threonine
(Ser/Thr) protein kinase and a key downstream effector of the
small GTPase Rho.12,13 ROCK forms a complex with Rho and it
regulates various physiological functions, such as gene expres-
sion, neural growth, chemotaxis, and smooth muscle contrac-
tion.14–17 There are two isoforms of ROCK: ROCK-1 and ROCK-
2, and they are extensively distributed in various tissues18; for
example, in ocular tissues, they are expressed in the ciliary
muscles, trabecular meshwork, iris, and retina.19 The Rho/
ROCK pathway is involved in various neuropathological
conditions, such as spinal cord injury,20 Alzheimer’s disease,21
and demyelinating disease,22,23 and ophthalmologic diseases,
such as glaucoma,24 corneal endothelial dysfunction,25 diabetic
retinopathy,26 and age-related macular degeneration.27 ROCK
signaling has therefore attracted interest as a potential
therapeutic target for these diseases.
Fasudil, a ROCK inhibitor, was approved in 1995 in Japan,
where it is used to suppress cerebral vasospasm by inhibition of
actomyosin contraction.13 ROCK inhibitors are also a novel
class of drugs in development to treat primary open angle
glaucoma, which lowers IOP by altering the arrangement of the
cytoskeleton and focal adhesions in trabecular meshwork
cells.28,29 In addition, fasudil attenuated the ischemia/reperfu-
sion-induced apoptosis of retinal cells in the inner retinal layers
(IRLs), including RGCs,30 and suppressed impairment of the
optic nerve head blood flow, function, and morphology.31
Ripasudil is a stronger inhibitor than previous ROCK inhibitors,
such as fasudil, by approximately 5 to 10 times. Topical
instillation of ripasudil reduced the IOP of rabbits32 and
monkeys.33 Ripasudil is the first ophthalmic solution approved
for the treatment of glaucoma and ocular hypertension in
Japan; in 2014, it became available in an eye drop form to
increase the outflow of the aqueous humor.34–36 In addition,
oral ripasudil protects RGCs after optic nerve injury by
suppressing oxidative stress via Nox1 downregulation,37 but
there are few reports about its neuroprotective effects. In the
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present study, we found that topical ripasudil prevents
glaucomatous retinal degeneration in EAAC1 KO mice by
stimulating an IOP-independent pathway, in addition to IOP-
dependent pathways.
MATERIALS AND METHODS
Mice
Experiments were performed using EAAC1 KO mice (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany)3,38,39 on a
C57BL6 background, in accordance with the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
Drug Administration
From 5 weeks of age (5 W) to 8 or 12 W, EAAC1 KO mice
received once-daily topical administration (5 lL/day) of
phosphate-buffered saline (PBS) as the control or two different
concentrations of ripasudil (Kowa Pharmaceutical Co. Ltd.,
Tokyo, Japan) solution: 0.4% and 2% in PBS. We selected these
doses of ripasudil because 0.4% is the clinical concentration
and 2% is the concentration that can be stably dissolved
without precipitation at normal temperature.
IOP Measurement
IOP was measured by a commercial rebound tonometer
(TonoLab; Colonial Medical Supply, Franconia, NH, USA) in
anesthetized mice, as reported previously.7,38,40 To minimize
variation, data were collected between 15:00 and 18:00, 4 to 6
minutes after injection of the anesthetic, during which time
IOP plateaus. IOP was measured at 5, 8, and 12 W.
Imaging Acquisition of Spectral-Domain Optical
Coherence Tomography (SD-OCT)
SD-OCT (RS-3000; Nidek, Aichi, Japan) examinations were
performed at 5, 8, and 12 W. For fundus imaging, polymethyl
methacrylate contact lenses optimal for mice (UNICON, Osaka,
Japan) were placed on the corneas. The lenses prevent
anesthesia-induced cataract progression. A 60-D adaptor lens
was placed on the objective lens of the Multiline OCT to focus
on the retina. All line scan images were location matched,
scanning vertically through the center of the optic nerve head
at three-disc diameter lengths above it.7,38,41 The average
thickness of the ganglion cell complex (GCC; between the
internal limiting membrane and the interface of the inner
plexiform layer and the inner nuclear layer) and the layers
other than GCC were measured. The maximum number of B-
scans set by the manufacturer (50) was used for averaging.
Histological and Morphometric Studies
Mice were perfused with Zamboni’s fixative (2% paraformal-
dehyde and 15% picric acid in 0.1 M phosphate buffer) at 5, 8,
and 12 W. Eyes were enucleated and postfixed in 3%
glutaraldehyde solution (3% glutaraldehyde, 9% formaldehyde,
37.5% ethanol, and 12.5% acetic acid in distilled water) for 2
hours. Paraffin-embedded retinal sections of 7-lm thickness
were cut through the optic nerve and stained with hematox-
ylin and eosin (H&E). The RGC number and the extent of
retinal degeneration were quantified in two ways.42 First, the
number of neurons in the ganglion cell layer (GCL) of the
retina was counted from one ora serrata through the optic
nerve to the other ora serrata. Second, in the same section, the
thickness of the IRL (between the internal limiting membrane
and the interface of the outer plexiform layer with the outer
nuclear layer) was measured.
Retrograde Labeling
Mice were deeply anesthetized with isoflurane (Intervet,
Tokyo, Japan), placed on a stereotaxic frame, and injected
with 2 lL of 1% Fluoro-Gold (FG; Fluorochrome LLC, Denver,
CO, USA) dissolved in PBS into the superior colliculus.7,42 Ten
days after FG application, mice were anesthetized, the eyes
were enucleated, and the retinas were isolated for whole
mount preparation. The retinas were fixed in 4% paraformal-
dehyde in PBS for 20 minutes and mounted on a glass slide
with a mounting medium (Vectashield; Vector Laboratories,
Burlingame, CA, USA), and the RGC density was examined
with a fluorescent microscope. The excitation and emission
wavelengths for FG were 323 and 620 nm, respectively. One
central (0.1 mm from the optic disc) and one peripheral (1.0
mm from the optic disc) areas (0.04 mm2) per quadrant of each
retina were chosen. FG-labeled cells were manually counted,
and the mean number of RGCs per square millimeter was
calculated.7,42
Multifocal Electroretinogram (mfERG)
Mice were anesthetized at 5, 8, and 12 W by intraperitoneal
injection of 87.5 mg/kg sodium pentobarbital. The pupils were
dilated with 0.5% phenylephrine hydrochloride and 0.5%
tropicamide. The mfERGs were recorded using a VERIS 6.0
system (Electro-Diagnostic Imaging, Redwood City, CA, USA).
The visual stimulus consisted of seven hexagonal areas scaled
with eccentricity. The stimulus array was displayed on a high-
resolution black-and-white monitor with a frame rate of 100
Hz. The second-order kernel, which is impaired in patients
with glaucoma, was analyzed as previously reported.3,7,40,43
Immunoblot Analyses
Immunoblotting was performed as previously reported.44
Membranes were incubated with an antibody against p38
(1:1000; sc-535; Santa Cruz, Santa Cruz, CA, USA) or
phosphorylated p38 (1:1000; 612280; BD Biosciences, San
Jose, CA, USA). The intensities were analyzed using ImageJ
(http://imagej.nih.gov/ij/; provided in the public domain by
the National Institutes of Health, Bethesda, MD, USA).45
Immunohistochemistry
Mice were perfused with Zamboni’s fixative at 12 W. Eyes were
enucleated, postfixed in Zamboni’s fixative for 2 hours, and
then transferred into a sucrose buffer (30% sucrose in a 0.1-M
phosphate buffer) for cryoprotection. Retinal cryostat sections
of 10-lm thickness were prepared and examined by immuno-
staining using an antibody against RBPMS (1:1000; ab194213;
Abcam, Cambridge, MA, USA), glutamine synthetase (GS;
1:1000; MAB302; Merck Millipore, Billerica, MA, USA),
Calretinin (1:1000; 66496-1-Ig; Proteintech, Chicago, IL,
USA), protein kinase C (PKC; 1:1000; 21991-1-AP; Protein-
tech), Calbindin (1:1000; 14479-1-AP; Proteintech), or phos-
phorylated p38 (1:1000). The intensities of phosphorylated
p38 at the GCL were analyzed using ImageJ.45
Statistics
Data are presented as mean 6 SEM. When statistical analyses
were performed, the Student’s t-test or 1-way ANOVA followed
by a Tukey’s test was used. P < 0.05 was regarded as
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statistically significant. JMP version 13.1.0 (SAS Institute, Inc.,
Cary, NC, USA) was used for the statistical analyses.
RESULTS
NTG-like Retinal Degeneration in EAAC1 KO Mice
We previously reported progressive RGC loss from 5 to 12 W in
EAAC1 KO mice.3 Consistently, the RBPMS-positive RGC
number was significantly decreased in EAAC1 KO mice
compared with wild-type (WT) mice at 12 W (Figs. 1A, 1B).
To examine the effects of EAAC1 on other retinal cell types, we
carried out immunohistochemistry with calretinin (a marker of
RGCs and amacrine cells), calbindin (a marker of horizontal
cells), PKC (a marker of bipolar cells), or GS (a marker of
Müller glial cells),46 but we could detect no differences in their
expression patterns between WT and EAAC1 KO mice (Fig.
1A).
We also visualized the retinal layers in living mice using SD-
OCT, a noninvasive imaging technique that can be used to
acquire cross-sectional tomographic images of the reti-
na.7,38,41 For quantitative analysis, GCC was measured by
scanning the retina in a circle centering around the optic
nerve disc (Fig. 1C), and the average GCC thickness was
determined from acquired images (Fig. 1D). The average
thickness of the GCC, which contains the nerve fiber layer,
GCL, and inner plexiform layer, was significantly smaller in
EAAC1 KO mice compared with WT mice (Fig. 1E). Whereas,
the thickness of the other retinal layers was similar between
WT and EAAC1 KO mice (Fig. 1F). These data reconfirmed our
previous findings showing NTG-like RGC degeneration in
EAAC1 KO mice.
Effects of Ripasudil on IOP in EAAC1 KO Mice
In this study, we topically administered daily ripasudil (0.4% or
2%) or PBS as a control to EAAC1 KO mice from 5 W through to
8 or 12 W (Fig. 2A) to investigate whether it is capable of
preventing NTG-like phenotypes. First, we examined the
effects of ripasudil on IOP. We previously reported that the
FIGURE 1. RGC degeneration in EAAC1 KO mice. (A) Immunostaining of the retina of WT and EAAC1 KO mice using cell type-specific markers.
Scale bar: 100 lm. (B) Quantification of the RBPMS-positive cells in (A). (C) An image of a circle centering around the optic disc. (D) An OCT
circular scan image captured from (C). (E, F) Longitudinal evaluation of the thickness of the GCC (E) and other layers (F) by a circular scan. The
thickness of the GCC (E) and other layers (F) in WT mice was estimated as 100%. The data are presented as mean 6 SEM of six samples for each
experiment. **P < 0.01.
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FIGURE 3. In vivo imaging of the retina in EAAC1 KO mice treated with ripasudil. (A) OCT cross-sectional images of retinas at 5, 8, and 12 W. (B)
Longitudinal evaluation of the GCC thickness by a circular scan. The data are presented as mean 6 SEM; there are 12 samples for 5 and 8 W and six
samples for 12 W. **P < 0.01, ***P < 0.001.
FIGURE 2. Experimental protocols and effects of ripasudil on IOP. (A) Experimental protocols. Ripasudil (0.4% or 2%; 5 lL) or PBS (5 lL) was
administered locally every day from 5 W. The mice were euthanized at 5, 8, or 12 W. (B) IOP at 5, 8, and 12 W. The data are presented as mean 6
SEM; there are 12 samples for 5 and 8 W and six samples for 12 W. *P < 0.05, **P < 0.01.
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IOP of EAAC1 KO mice was not significantly increased
compared with WT mice at 5, 8, and 12 W.3 At both
concentrations, ripasudil slightly but significantly reduced
IOP in EAAC1 KO mice compared with the control (Fig. 2B).
There was no significant difference between the two
concentrations.
Ripasudil Protects RGCs in EAAC1 KO Mice
We next examined the GCC thickness at 8 and 12 W in EAAC1
KO mice treated with 0.4% and 2% ripasudil using SD-OCT.
GCC thickness was greater in ripasudil-treated EAAC1 KO mice
than control EAAC1 KO mice (Fig. 3A). Quantitative analysis
showed that GCC thickness at 8 and 12 W was significantly
decreased in control mice, but it was almost unaltered in mice
treated with 0.4% and 2% ripasudil (Fig. 3B). There was no
significant difference between the two concentrations. These
data indicate that both concentrations protect RGCs from
NTG-like neurodegeneration.
We previously reported that the cell number in the GCL of
EAAC1 KO mice at 8 and 12 W was significantly lower than WT
mice.3,7 In addition, the thickness of the IRL in EAAC1 KO mice
was significantly reduced at 8 and 12 W.3 The number of
surviving neurons in EAAC1 KO mice treated with 0.4% or 2%
ripasudil was significantly greater than that in control mice at 8
and 12 W (Figs. 4A, 4B). In addition, both concentrations of
ripasudil treatment prevented the thinning of the IRL (Fig. 4C).
There was no significant difference between the two
concentrations. Because GCL contains cell types other than
RGCs, including displaced amacrine cells,47 we next per-
formed retrograde labeling of RGCs with FG on control and
ripasudil-treated mice at 8 W. In this experiment, we used the
lower dose only because the neuroprotective effect was similar
between 0.4% and 2% (Fig. 4). Consistent with the results of
cell counting in the GCL (Fig. 4B), the RGC number in
ripasudil-treated EAAC1 KO mice was significantly higher than
control mice in both the central and peripheral regions (Fig. 5).
These data demonstrate that topical ripasudil prevents RGC
death all across the retina in EAAC1 KO mice.
Ripasudil Ameliorates Visual Impairment in EAAC1
KO Mice
To determine if the histological observation of ripasudil-
mediated neuroprotection in EAAC1 KO mice reflects func-
tional aspects, we examined retinal function using mfERG. We
analyzed the second-order kernel component, which appears
to be a sensitive indicator of inner retinal dysfunction and is
FIGURE 4. Effects of ripasudil on retinal degeneration in EAAC1 KO mice. (A) H&E staining of retinal sections. Scale bar: 100 and 50 lm in the
upper and immediately lower panels, respectively. INL, inner nuclear layer; ONL, outer nuclear layer. (B, C) Quantification of the cell number in the
GCL (B) and IRL thickness (C). The data are presented as mean 6 SEM of six samples for each experiment. *P < 0.05, **P < 0.01, ***P < 0.001.
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impaired in glaucoma patients.43,48 The response topography
demonstrating the second-order kernel component revealed
that the average retinal responses were impaired in all visual
fields in EAAC1 KO mice, but 0.4% and 2% ripasudil treatment
ameliorated the deterioration in retinal function (Fig. 6). There
was no significant difference between the two concentrations.
These results confirm that the neuroprotective effects of
ripasudil on glaucomatous retinal degeneration in EAAC1 KO
mice are functionally significant.
Ripasudil Decreases Phosphorylated p38 in EAAC1
KO Mice
We next investigated other potential mechanisms underlying
ripasudil-mediated neuroprotection besides IOP lowering (Fig.
2B). We previously reported that EAAC1 KO mice were in an
oxidative condition due to decreased glutathione synthesis.2,3
It has been reported that activating the phosphorylation of p38
MAPK is associated with the intracellular level of ROS and the
ASK1-p38 signaling is involved in RGC death in the glaucoma-
tous retina.40,49 Thus, we evaluated the protein levels of p38 in
EAAC1 KO mice at 5 W, and we found that the ratio of
phosphorylated p38 was increased in EAAC1 KO mice
compared with WT mice (Fig. 7A). These results suggested
that p38-mediated RGC death occurs independent of IOP.
Next, we examined the protein levels of p38 in control and
0.4%-ripasudil-treated EAAC1 KO mice at 8 W. The ratio of
phosphorylated p38 was strongly increased in control EAAC1
KO mice, but ripasudil treatment significantly suppressed the
ratio (Fig. 7B). We observed no marked changes in the protein
levels of the total p38 in any groups. We also performed
immunohistochemical analysis of phosphorylated p38 in the
mouse retina at 8 W. Phosphorylated p38 was mainly observed
in the GCL of EAAC1 KO mice, and it was barely detected in
WT mice or ripasudil-treated EAAC1 KO mice (Fig. 7C).
Quantitative analyses confirmed that the phosphorylation of
p38 is significantly suppressed with ripasudil treatment in
EAAC1 KO mice (Fig. 7D).
DISCUSSION
In this study, we showed that topical administration of
ripasudil reduced the IOP of EAAC1 KO mice. We also showed
that phosphorylation of p38, which is indicative of increased
oxidative stress, is reduced in EAAC1 KO mice with ripasudil
treatment. Consistently, ripasudil prevented progressive RGC
death, thinning of the IRL, and impairment in retinal function
in EAAC1 KO mice. To monitor these changes in the same
animal, we used OCT and mfERG that permit in vivo,
noninvasive, quantitative assessments of the changes in retinal
morphology and function in EAAC1 KO mice. These tech-
niques clearly visualized the therapeutic effects of ripasudil and
provide useful information in experimental animals and for
clinical trials and management. We tested two concentrations,
0.4% and 2%, but there were no differences in the therapeutic
effects, suggesting that the lower concentration was sufficient
to evoke the maximum therapeutic response. We demonstrat-
ed that the topical administration of ripasudil reduces IOP and
the activation of p38 in EAAC1 KO mice, which leads to
suppression of glaucomatous neurodegeneration.
ROCK inhibitors may be drug candidates for neuroprotec-
tion as well as lowering IOP. For example, fasudil attenuated
the ischemia/reperfusion-induced apoptosis of retinal cells
independent of changes in IOP.30 We previously reported that
brimonidine exerted neuroprotective effects on glaucomatous
degeneration in EAAC1 KO mice.50 Brimonidine is known to
lower IOP and have neuroprotective effects in glaucoma
patients.51 Since ripasudil showed a similar reduction rate of
IOP and neuroprotection in EAAC1 KO mice, we think it is
plausible that ripasudil also prevents RGC death through both
IOP-dependent and IOP-independent pathways.
We previously reported that traumatic optic nerve injury
activates p38 and that intraocular injection of a p38 inhibitor
prevents RGC death.41,52 In this study, we detected phosphor-
ylated p38 in the GCL of EAAC1 KO mice independent of IOP,
but topical ripasudil significantly suppressed its activity (Fig.
7). These findings are consistent with the previous reports that
other ROCK inhibitors, such as fasudil and H1152, suppressed
stress-activated MAPK family members (p38 and c-Jun N-
terminal kinase [JNK]).53–55 The inhibition of p38 has been
shown to be potentially beneficial in experimental nerve
trauma, excitotoxicity,56 and growth factor withdrawal.57 As a
result, p38 inhibitors have recently been claimed as novel and
potential therapeutics for neurodegenerative diseases.58,59
These findings suggest that inhibition of p38 may be
therapeutically effective in protecting degenerating RGCs from
various pathological conditions, including glaucoma.
ROCK inhibitors also have vascular smooth muscle relaxant
action and were originally used to treat vasospasm cerebral
infarction after subarachnoid hemorrhage.60 ROCK inhibitors
increase the blood flow in the optic nerve head.31,61 Decreased
blood flow to the eye is one of the risk factors of glaucoma.2,62
In addition, ripasudil may suppress TNF-induced optic nerve
FIGURE 5. Effects of 0.4% ripasudil on RGC degeneration in EAAC1 KO
mice. (A) Representative images of retrograde-labeled RGCs in the
central and peripheral retina at 8 W. Scale bar: 100 lm. (B)
Quantitative analyses of RGCs in the central and peripheral areas of
the retina. The data are presented as mean 6 SEM of four samples for
each experiment. *P < 0.05.
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degeneration by modulating autophagy,63 so ripasudil may
suppress glaucoma through multiple neuroprotective effects.
In this study, we have used EAAC1 KO mice as an animal
model of NTG. This model closely mimics pathology of NTG,
including RGC loss, optic nerve atrophy, and visual impairment
while maintaining normal IOP.3 However, there are some
limitations to using mouse models. For example, the RGC loss
in EAAC1 KO mice is distributed across the entire retina, rather
than in specific regions as seen in human glaucoma and in
some mouse models of ocular hypertension induced glauco-
ma,64,65 and retinal degeneration in EAAC1 KO mice starts at 5
weeks of age, earlier and faster time-course than one may
expect from human glaucoma. Despite some limitations, such
animal models are essential for preclinical research and our
NTG models have been providing useful information regarding
NTG therapy easily and speedily. We recently reported that
widely prescribed drugs, such as valproic acid,45 candesar-
tan,38 and edaravone7 suppressed RGC death in EAAC1 or
GLAST KO mice without altering IOP. In addition, every other
day fasting, a form of caloric restriction, suppressed RGC death
in EAAC1 KO mice under normal IOP.66 These findings raise
intriguing possibilities for the management of glaucoma by
caloric restriction and/or utilizing existing drugs for neuropro-
tection in combination with conventional treatments to lower
IOP.2,50,67,68 Further studies will be required to determine the
long-term effect of ripasudil on p38 activation and ocular blood
flow in EAAC1 KO mice and other animal models of glaucoma.
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